Cancer stem cells (CSC) possess abilities generally associated with embryonic or adult
stem cells, especially self-renewal and differentiation. The CSC model assumes that this …

Therapy resistance can arise within tumor cells because of genetic or phenotypic changes
(intrinsic resistance), or it can be the result of an interaction with the tumor microenvironment …

Polyploid giant cancer cells (PGCCs) have been observed by pathologists for over a
century. PGCCs contribute to solid tumor heterogeneity, but their functions are largely …

Interactions with the immune system may lead tumorigenic cells into dormancy. However,
the underlying molecular mechanism is poorly understood. Using a 3D fibrin gel model, we …

Although many drugs/treatments are now available for most diseases, too often, resistance
to these treatments impedes complete therapeutic success. Acquired resistance is a major …

Hypoxia exerts a profound impact on diverse aspects of cancer biology. Increasing evidence
has revealed novel functions of hypoxia in cancer cell epigenomics, epitranscriptomics …

The relationships between cancer and stemness have a long history that is traced here.
From the mid‐19th century when the first theory on the embryonic origin of cancer was …

Tumor evolution presents a formidable obstacle that currently prevents the development of
truly curative treatments for cancer. In this perspective, we advocate for the hypothesis that …

Cancer stem cells (CSC) possess abilities generally associated with embryonic or adult
stem cells, especially self-renewal and differentiation, but also dormancy and cellular …

Somatic evolution during cancer progression and therapy results in tumour cells that show a
wide range of phenotypes, which include rapid proliferation and quiescence. Evolutionary …